FDA approval for Ibrance in men with breast cancer sets precedent for use of realworld evidence

FDA approval for Ibrance in men with breast cancer sets precedent for use of real-world evidence

On 4 April the US Food and Drug Administration (FDA) announced its extension of the indication of Ibrance (palbociclib) in...
Read More...

More From BioPortfolio on "FDA approval for Ibrance in men with breast cancer sets precedent for use of real-world evidence"